Dimitri BEDO retweeted
Arteriovenous fistula for haemodialysis as a predictor of de novo heart failure in kidney transplant recipients
doi.org/10.1093/ckj/sfae105
Dimitri BEDO retweeted
#ACC25 #CircSimPub In a prespecified analysis of the SOUL trial, oral semaglutide reduced MACE outcomes independently of concomitant SGLT2i use in patients with T2DM and ASCVD and/or CKD. GLP1-RA and SGLT2i can be saf... ahajrnls.org/41RZkDd #AHAJournals @Dr_Birkenfeld @RBusui
Dimitri BEDO retweeted
Early and Sensitive Detection of #Cisplatin Induced #KidneyInjury Using Novel #Biomarkers
#VisualAbstract by @jmteakell
kireports.org/article/S2468-…
Dimitri BEDO retweeted
Le SNIN tient à vous souhaiter une belle et heureuse année 2025 🥳
On en profite pour vous présenter le bureau 2024/2025 ✨ (un peu tardivement, mais mieux vaut tard que jamais !!)
Le meilleur reste à venir ! 🫡
Dimitri BEDO retweeted
Now online in @NDTsocial
Tissue fibrosis in cardiorenal syndrome: crosstalk between heart and kidneys
🧐 The repair process in cardiorenal injury involves a regenerative phase characterized by proliferation and polyploidization.
▶️academic.oup.com/ndt/article…
Dimitri BEDO retweeted
LAURÉATS 2024]
🏅Félicitations à @RaphaelCarapito, lauréat du prix Éloi Collery pour ses travaux sur la #pathologie #alloimmunes et #autoimmunes/#inflammatoires
@CHRUStrasbourg @inserm
🛜 bit.ly/3ZYIAZG
Dimitri BEDO retweeted
Type 2 myocardial infarction: challenges in diagnosis and treatment. Read this State-of-the-Art Review just published in #EHJ 👉 bit.ly/3VBGdd4
@RoccoMontone @ehj_ed
Dimitri BEDO retweeted
Atrial fibrillation (AF) is associated with increased rates of stroke, heart failure, and mortality. This narrative review examines the epidemiology, pathophysiology, diagnosis, and treatment of AF.
ja.ma/3ZDdZ2D
Dimitri BEDO retweeted
🧐Selected from our joint @ERAkidney and @escardio Cardio-Kidney Collection:
academic.oup.com/ndt/pages/j…
➡️Proximal versus distal diuretics in congestive heart failure
🔓doi.org/10.1093/ndt/gfae058
Dimitri BEDO retweeted
The long-term effects of dapagliflozin in chronic kidney disease: a time-to-event analysis
🆓doi.org/10.1093/ndt/gfae106
Dimitri BEDO retweeted
SGLT2 Inhibitor #SGLT2i in #Diabetic and #NonDiabetic Renal #Transplant Recipients
#VisualAbstract by @DrPSVali
kireports.org/article/S2468-…
Dimitri BEDO retweeted
Changing treatment paradigms for membranous nephropathies
🆓doi.org/10.1093/ndt/gfae141
Dimitri BEDO retweeted
Original Article: Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease (EPIC-CAD) nej.md/3Z1D1d3
Editorial: Atrial Fibrillation and Stable Coronary Artery Disease nej.md/3T5MV9G
#Cardiology
![Kaplan–Meier estimates of the incidence at 12 months of net adverse clinical events (primary outcome), defined as a composite of death from any cause, myocardial infarction, stroke, systemic thromboembolic event, unplanned urgent revascularization, or major bleeding or clinically relevant nonmajor bleeding (as defined by the International Society on Thrombosis and Haemostasis [ISTH]).](https://pbs.twimg.com/media/Gd_LBVOasAAo7rv.png?name=small&format=webp)
ALT Kaplan–Meier estimates of the incidence at 12 months of net adverse clinical events (primary outcome), defined as a composite of death from any cause, myocardial infarction, stroke, systemic thromboembolic event, unplanned urgent revascularization, or major bleeding or clinically relevant nonmajor bleeding (as defined by the International Society on Thrombosis and Haemostasis [ISTH]).
Dimitri BEDO retweeted
Intensive Blood-Pressure Control in Patients with Type 2 Diabetes: @NEJM
🥸 Day 3 of #AHA24 continues: Great work @AHAScience
😱 Let's summarize BPROAD trial
👇👇👇
Dimitri BEDO retweeted
Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity: @NEJM
🥸The SUMMIT trial - @AHAScience
😱 Summary
👇👇👇
Dimitri BEDO retweeted
In the CLEAR randomized trial involving patients with acute myocardial infarction, colchicine did not decrease the risk of major adverse cardiovascular events over a median follow-up period of 3 years. Full trial results: nej.md/4i2U6dV
Dimitri BEDO retweeted
Presented at #ACR24:
In the MITIGATE involving 135 participants with IgG4-related disease, inebilizumab was associated with significantly lower flare risk and greater likelihood of complete remission than placebo at 1 year. Full trial results: nej.md/4euxr6Y
Dimitri BEDO retweeted
The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial
🔓doi.org/10.1093/ndt/gfae263
Dimitri BEDO retweeted
Le groupe Spiesser et la base Astre sont encore à l’honneur à la #SFNDT2024 avec le travail de Dimitri Bedo sur les événements cardio vasculaires en post greffe
Dimitri BEDO retweeted
Original Article: Atrasentan in Patients with IgA Nephropathy (ALIGN) nej.md/3NzvISW
Editorial: Waystations in Progress — Burgeoning Treatment Options for IgA Nephropathy nej.md/4fdz9dV
#KidneyWk | @ASNKidney






































